EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY-NC-ND 4.0

Effectiveness and safety of elexacaftor/tezacaftor/ivacaftor treatment in children aged 6‐11 years with cystic fibrosis in a real‐world setting

Valeria Daccò, Chiara Rosazza, Alessandra Mariani, Carmela Rizza, Nicolò Ingianni, Erica Nazzari, Vito Terlizzi iD, Francesco Arturo Blasi, Gianfranco Alicandro iD

Pediatric Pulmonology · 2024

DOI: 10.1002/ppul.27125 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Pediatric Pulmonology, 2024. Verfasst von Valeria Daccò und 8 weiteren Autor:innen. Beteiligte Einrichtung: Pediatric Department, Cystic Fibrosis Pediatric Center, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy. Hauptthemen laut MEDLINE: Cystic Fibrosis, Benzodioxoles, Drug Combinations, Aminophenols. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Italian Ministry of Health, Ricerca Corrente 860/01/2023.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Elexacaftor‐tezacaftor‐ivacaftor (ETI) is a highly effective cystic fibrosis (CF) transmembrane conductance regulator (CFTR) modulating therapy for people with CF and at least one F508del variant. However, there is limited data about the safety and efficacy of this therapy in pediatric populations and in real‐world settings. This study aimed at evaluating the effectiveness, tolerability, and safety of ETI in children with CF.

Methods

This was a prospective observational study including all children aged 6–11 years who initiated ETI therapy between October 2022 and March 2023 at the Pediatric CF Center of Milan (Italy). Study outcomes included changes in sweat chloride concentration, FEV 1 , LCI 2.5 , body mass index (BMI), tolerance, and safety. Mean changes in study outcomes from baseline through 24 weeks were estimated using mixed‐effects regression models.

Results

The study included 34 children with CF (median age: 8.3 years). At Week 12, we observed an average decrease in LCI 2.5 of 2.3 units (95% confidence interval [CI]: −3.1; −1.5). At Week 24, sweat chloride concentration decreased by 63 mEq/L (95% CI: −69; −58), FEV 1 increased by 8.8 percentage point (95% CI: 3.7; 13.9) and BMI increased by 0.15 standard deviation scores (95% CI: 0.04; 0.25). Skin rashes appeared in 6 patients which spontaneously resolved within a few days. One month after treatment initiation, one patient experienced an elevation in liver function test results, which subsequently decreased during follow‐up visits without necessitating discontinuation of therapy.

Conclusions

Our data indicate that ETI therapy is well tolerated by children with CF and is effective in improving signs of lung function abnormalities from early childhood.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cystic FibrosisBenzodioxolesDrug CombinationsAminophenolsIndolesHumansChildMaleFemaleProspective StudiesItalyTreatment OutcomeQuinolonesPyridinesCystic Fibrosis Transmembrane Conductance RegulatorPyrazolesForced Expiratory VolumeSweatChloride Channel AgonistsQuinolines

Stichwörter der Autor:innen

CFTR modulatorsElexacaftorIvacaftorTezacaftorchildrencystic fibrosis

Substanzen

BenzodioxolesDrug CombinationsAminophenolsIndolesQuinolonesPyridineselexacaftor, ivacaftor, tezacaftor drug combinationCystic Fibrosis Transmembrane Conductance RegulatorPyrazolesChloride Channel Agonists

Autor:innen und Institutionen

  • Pediatric Department, Cystic Fibrosis Pediatric Center, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
  • Department of Pediatric Medicine, Meyer Children's Hospital IRCCS, Cystic Fibrosis Regional Reference Center, Florence, Italy.
  • Medical Department, Respiratory Unit and Cystic Fibrosis Adult Center, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
  • Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy.

ORCID-Profile: Vito Terlizzi, Gianfranco Alicandro

Förderung

  • Italian Ministry of Health, Ricerca Corrente 860/01/2023

Zitieren

APA

Daccò, V., Rosazza, C., Mariani, A., Rizza, C., Ingianni, N., Nazzari, E., Terlizzi, V., Blasi, F. A., & Alicandro, G. (2024). Effectiveness and safety of elexacaftor/tezacaftor/ivacaftor treatment in children aged 6‐11 years with cystic fibrosis in a real‐world setting. Pediatric Pulmonology. https://doi.org/10.1002/ppul.27125

Vancouver

Daccò V, Rosazza C, Mariani A, Rizza C, Ingianni N, Nazzari E, et al. Effectiveness and safety of elexacaftor/tezacaftor/ivacaftor treatment in children aged 6‐11 years with cystic fibrosis in a real‐world setting. Pediatric Pulmonology. 2024. doi:10.1002/ppul.27125

BibTeX
@article{Dacc2024,
  author = {Daccò, Valeria and Rosazza, Chiara and Mariani, Alessandra and Rizza, Carmela and Ingianni, Nicolò and Nazzari, Erica and Terlizzi, Vito and Blasi, Francesco Arturo and Alicandro, Gianfranco},
  title = {Effectiveness and safety of elexacaftor/tezacaftor/ivacaftor treatment in children aged 6‐11 years with cystic fibrosis in a real‐world setting},
  journal = {Pediatric Pulmonology},
  year = {2024},
  doi = {10.1002/ppul.27125}
}
Kostenlos starten →